Journal
PHARMACEUTICS
Volume 12, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics12060526
Keywords
mesoporous silica nanoparticles; co-delivery; drug delivery; nucleic acids; gene transfection; nanomedicine
Categories
Funding
- European Research Council (Grant VERDI
- ERC-2015 AdG) [694160]
- Sara Borrell research contract from the Institute of Health 'Carlos III' of the Ministry of Science and Innovation - European Social Fund (ESF) [CD19/00250CP15/00103]
Ask authors/readers for more resources
Mesoporous silica nanoparticles have attracted much attention in recent years as drug and gene delivery systems for biomedical applications. Among their most beneficial features for biomedicine, we can highlight their biocompatibility and their outstanding textural properties, which provide a great loading capacity for many types of cargos. In the context of cancer nanomedicine, combination therapy and gene transfection/silencing have recently been highlighted as two of its most promising fields. In this review, we aim to provide an overview of the different small molecule drug-nucleic acid co-delivery combinations that have been developed using mesoporous silica nanoparticles as carriers. By carefully selecting the chemotherapeutic drug and nucleic acid cargos to be co-delivered by mesoporous silica nanoparticles, different therapeutic goals can be achieved by overcoming resistance mechanisms, combining different cytotoxic mechanisms, or providing an additional antiangiogenic effect. The examples here presented highlight the great promise of this type of strategies for the development of future therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available